Business Context and Reporting Period
This Form 8-K, filed on December 31, 2019, reports the consummation of a reverse acquisition by Intellisense Solutions Inc. (the "Company") of ScoutCam Ltd. ("ScoutCam"), a subsidiary of Medigus Ltd. Effective December 30, 2019, ScoutCam became the accounting acquirer, and the Company's historical financial statements will reflect ScoutCam's operations. ScoutCam specializes in miniaturized imaging technology (micro ScoutCam) for medical, defense, aerospace, and industrial applications. The Company is now a "smaller reporting company" with principal executive offices in Tel Aviv, Israel.
Key Financial Metrics
Revenue and Profitability (ScoutCam Carve-Out Data):
- Year Ended Dec 31, 2018: Revenues of $391,000; Operating Loss of $523,000.
- Nine Months Ended Sept 30, 2019: Revenues of $272,000; Operating Loss of $1,055,000.
- Gross Margin: Turned negative in the nine months ended Sept 30, 2019, with a gross loss of $168,000 due to product mix changes and payroll reclassification.
Liquidity and Capital Resources:
- Cash Balance: Approximately $3,202,088 immediately following the transaction closing.
- Financing: Raised approximately $3.3 million from investors via a Securities Purchase Agreement concurrent with the closing.
- Debt: ScoutCam holds a $500,000 line of credit and a $130,000 bridge loan from Medigus, both due upon or shortly after the closing.
- Going Concern: The filing states there is substantial doubt about the Company's ability to continue as a going concern within the first year following the closing without additional funding.
Material Changes vs. Prior Period
Operational Shift: The Company transitioned from a shell entity with no significant operations to an active business focused on custom-tailored visualization solutions. Historical financials now reflect ScoutCam's results rather than Intellisense's.
Financial Performance:
- Operating losses increased significantly in the nine months ended Sept 30, 2019 ($1.055M) compared to the same period in 2018 ($361K), driven by a $279,000 decrease in gross profit and a $389,000 increase in general and administrative expenses due to the reorganization and employee transfers from Medigus.
- Revenue remained relatively flat year-over-year for the nine-month period ($272K vs $266K), but the cost of revenues increased by 184% due to payroll reclassification and product mix changes.
Capital Structure: Medigus now owns 60% of the Company's outstanding shares. Additional shares were issued to investors for $3.3 million, and warrants were issued with exercise prices based on pre-money valuations of $16M and $24M.
Guidance, Outlook, and Risks
Outlook and Management Commentary:
- Management plans to integrate ScoutCam's business as the primary activity, targeting expansion into non-medical sectors (defense, aerospace, automotive).
- The Company intends to purchase a manufacturing facility in Israel in the near term but has not yet executed such an acquisition.
- Future growth is heavily dependent on the commercialization of the micro ScoutCam technology and securing additional financing.
Material Risks:
- Going Concern: Substantial doubt exists regarding the ability to continue operations for 12 months without further fundraising.
- Supplier Dependency: Reliance on a single supplier for CMOS miniature video sensors without a contractual commitment for quantity.
- Regulatory and Market Acceptance: Success depends on market acceptance in medical and non-medical industries and obtaining necessary regulatory approvals (FDA, CE).
- Geopolitical: Operations are based in Israel, exposing the Company to regional political, economic, and military instability.
- Stock Liquidity: Common Stock is quoted on the OTC Markets (Pink Tier) with no established trading market; classified as a "penny stock."
Unusual Items: The transaction is treated as a reverse acquisition. The Company is subject to a one-year waiting period before Rule 144 can be utilized for the resale of restricted securities due to its prior status as a shell company.
Investor Verification Checklist
- Verify the Company's ability to secure additional funding to address the "substantial doubt" regarding its going concern status.
- Confirm the status of the single-source supplier for CMOS sensors and any efforts to secure alternative supply chains.
- Review the progress of regulatory approvals (FDA/CE) for current and future commissioned products.
- Monitor the execution of the planned manufacturing facility acquisition in Israel.
- Assess the trading volume and liquidity of the Common Stock on the OTC Markets (Symbol: INLL).
- Track the achievement of the $33 million sales milestone within three years, which would trigger an additional 10% equity issuance to Medigus.